On November 6, Charles River Laboratories rose 5.68% in Regular Trading, trading at $330.64/share, with turnover of $21.03 million.
The clearest catalyst was a fresh analyst action: Jefferies raised its price target on Charles River Laboratories to $385 from $340, above the FactSet-tracked average target of $358.07, reinforcing attention on potential valuation re-rating.
The backdrop is the company’s latest quarterly report released on November 4. Charles River Laboratories posted adjusted EPS of $3.09, above the $2.97 market expectation, and revenue of $982.7 million, ahead of the $960.4 million consensus. The company also lifted its full-year non-GAAP EPS guidance to $11.35-$11.55 and narrowed its expected full-year revenue decline to 2% to 1.5%, indicating improving profit recovery even as revenue remains below the prior-year level.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)